euro adhoc: Intercell AG
Personnel
Intercell AG appoints two senior vaccine
executives to the Supervisory Board
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
15.05.2006
Intercell AG (VSE, "ICLL") today announced that the following persons have been appointed new members of the supervisory board in the course of Intercells Annual General Meeting on May 12, 2006 as new members of the supervisory board:
Staph Bakali served as Chief Operating Officer of ID Biomedical. He played a significant role in transforming ID Biomedical from an R&D organization into a fully-integrated biotech company. He was significantly involved in the acquisition of Shire Biologics by ID Biomedical and led the integration efforts. In 2005, ID Biomedical itself was acquired by GlaxoSmithKline. Before his tenure at ID Biomedical, Mr. Bakali has gained significant entrepreneurial experience in building and managing successful companies in the vaccine industry in his previous roles at PowderJect, Chiron and Smithkline Beecham.
Hans Wigzell served as a Chief Scientific Advisor to the Swedish government since 1999, and is also a Professor at the Karolinska Institute in Stockholm and board member of several companies and foundations in Sweden, EU and USA. He spent most of his research career at the Karolinska Institute where he graduated in 1967, becoming Professor of Immunology in 1982 and President of the Karolinska Institute from 1995 to 2003. He is a member of several Swedish and International academies and served as a chairman of the Nobel Committee for Physiology or Medicine from 1990 to 1993.
end of announcement euro adhoc 15.05.2006 17:04:56
Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market